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ABSTRACT: 
Oropharyngeal cancers (OPC) are subdivide in two different entities based on HPV 
infections, which are mainly by p16 subtype alone, due to better overall survival (OS) rates. 
However differences in the techniques used and the few cohorts looking for other HPV 
subtypes suggest the necessity to approach this further. Moreover, there is still a group of 
HPV+ patients that present a lethal and aggressive disease. Cyclin D1 overexpression has 
been proposed as a possible marker to better stratify these patients although results 
differed among studies. Due to that, this study aimed to assess HPV prevalence and 
subtypes in a cohort of 54 OPC patients from HUMV as well as Cyclin D1 expression among 
them to determine its effect on prognosis. Our results show a high HPV prevalence (38% of 
patients) and confirm HPV patients increased OS (p=0,035). p16 was the most common 
HPV-subtype (50%), followed by 59, 58 and 53. 38% of patients had multiple infections 
strongly contrasting with other cohorts (5%). Moreover, not significant differences were 
observed when looking at HPV+/cyclin D1 positive patients OS (p=0,933). However, due to 
low sample number and different cut-offs in other studies we can´t affirm this forcefully so 
further analysis should be done. 
Key words: Oropharyngeal cancer, Cyclin D1, human papillomavirus 
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RESUMEN: 
Los cánceres de orofaringe (CO) se pueden dividir en dos entidades diferentes en función 
de las infecciones por VPH, principalmente causadas por el subtipo 16, debido a una mejor 
supervivencia. Sin embargo, las diferencias en las técnicas usadas y las pocas cohortes 
mirando otros subtipos del VPH sugieren la necesidad profundizar más en este campo. 
Además, hay un grupo de pacientes VPH+ que presentan una enfermedad más letal y 
agresiva. La sobreexpresión de Ciclina D1 ha sido propuesta como un posible marcador 
para mejorar la estratificación de estos pacientes aunque los resultados difieren entre 
diferentes estudios. Debido a esto, este estudio tuvo el objetivo de determinar la 
prevalencia de VPH y sus subtipos en una cohorte de 54 pacientes de CO del HUMV así 
como la expresión de Ciclina D1 entre ellos para determinar los efectos en el pronóstico.  
Nuestros resultados muestran una prevalencia del 38% para el VPH y confirma el aumento 
de supervivencia entre estos pacientes (p=0,035). El subtipo 16 fue el más común (50%), 
seguido por 59, 58 y 53. El 38% de los pacientes están infectados por múltiples subtipos lo 
que contrasta con otras cohortes (5%). Además, no vimos diferencias significativas en la 
supervivencia cuando miramos a los pacientes positivos para VPH y Ciclina D1 (p=0,933). 
Sin embargo, debido al bajo número de muestras y diferencias en el corte en la expresión 
de Ciclina D1 no podemos afirmar esto por lo que nuevos análisis deben de hacerse.  
Palabras Clave: Cáncer de orofaringe, Ciclina D1, virus del papiloma humano  
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1. INTRODUCTION 
Oropharyngeal cancers are a common malignancy in the head and neck region and more 
than 90% are squamous cell carcinomas (1). In 2018, there were estimated 92,887 newly 
diagnosed oral cancer patients and 51,005 deaths from them worldwide which shows their 
significant incidence and mortality (2). The anatomic location of these cancers largely 
influences their associated risk factors, treatment options, and related epidemiologic 
characteristics (3). The term “oropharynx” refers to the posterior 1/3 of the tongue, 
palatine and lingual tonsils, soft palate, and the posterior pharyngeal wall (4) (5).  
Both oral cavity and oropharyngeal cancer have been related to cigarette smoking and 
alcohol consumption (6-8). However, although documented decreases in both these 
factors only oral cavity carcinomas incidence rates are decreasing while oropharyngeal 
carcinomas (OPC) are reaching epidemic levels (7, 9). This suggests differences in their 
biology and the presence of other major risk factors. Indeed, oropharyngeal cancer is 
tightly related to chronic latent infections of the human papillomavirus (HPV) (10-12). For 
instance, HPV detection in OPC has increased from 16% to 73% in the United States 
indicating a profound epidemiologic shift from carcinogen-induced to HPV-associated OPC 
(11, 13). HPV infection has been related to cervix cancer and the main HPV-types 
accounting for 70% of the cases are Type 16 and Type 18 (14-16). However, HPV-positive 
OPCs are HVP-16 in 95% of the cases (11, 17, 18). HPV infection is sexually transmitted and 
the increase of incidence can be explained by the changes in sexual behaviors that have 
occurred in the last years (16, 19-21). HPV+ OPC patients have remarkably higher overall 
survival than those without HPV-disease (13, 22-24). In a multicenter cohort study 
researches saw that 5-year overall survival was similar for 7th edition TNM stage I, II, III, 
and IVA but was lower for stage IVB and that it did not differ among N0, N1–N2a and N2b 
subsets, but was significantly lower for those with N3 disease (13). Therefore, in the 8th 
edition TNM staging it was included a separate classification for p16-positive and p16-
negative oropharyngeal cancer, a surrogate marker for oncogenic HPV. The T classification 
remains the same, except for carcinoma in situ (Tis) and T4b category that have been 
removed from HPV-positive disease. A key change is in the N category. In HPV-related 
carcinoma it is based on lymph node size (>6 cm in greatest dimension; cN3) and presence 
in the contralateral neck (cN2). Whereas, in HPV-negative cancer, extranodal extension 
defines cN3 category, independently of single ipsilateral lymph node ≤3 cm (cN1) or 
single/multiple metastasis in ipsilateral/bilateral/contralateral lymph nodes <6 cm (cN2). 
These modifications result in relative downstaging for HPV-positive patients – due to N 
criteria – and upstaging for HPV-negative patients – due to extranodal extension (25). 
However, the biological phenotypes of tumors are often divergent despite identical 
staging, resulting in different clinical outcomes and response to the selected treatment so 
new prognostic biomarkers are key to better stratify the risk in HPV-positive patients for 
determining appropriate therapy (26-28).  
One molecular marker that has been related to HPV-related cancer aggressiveness has 
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been Cyclin D1 by either gene amplification (26), rearrangement (29) or overexpression 
(28, 30). Cyclin D1 functions as a mitogen sensor and allosteric activator of cyclin 
dependent kinase 4 and 6 (CDK4/CDK6) regulating cell cycle transition from G1 to S phase, 
which in turn phosphorylate the retinoblastoma protein (Rb) which results in its functional 
inactivation releasing E2F family transcription factors from Rb-dependent repression. This 
allows the activation of a variety of genes promoting the entry and progression through S 
phase (31-33). In addition, cyclin D1 is capable to sequester CDK inhibitors, such as the 
INK4 family where p16- INK4a plays a crucial role CIP and KIP family that includes 
p21CDKN1A and p27-CDKN1B, increasing signalling efficiency (32, 34, 35). E6 and E7 HPV 
viral oncoproteins inactivate p53 and the retinoblastoma protein pRb causing p16 protein 
overexpression that leads to an inhibition and reduce levels of Cyclin-D1-CDK4/6 due to 
loss of the pRb negative feedback loop (36-38). Therefore, cyclin D1 downregulation has 
been linked to HPV-positive cancers and its overexpression has been seen to confer poor 
outcome (28, 39, 40). However, there is not a large amount of evidence suggesting its 
prognostic significance in oropharyngeal cancer due to high heterogeneity among studies. 
 Given that HPV associated oropharyngeal cancers are becoming an epidemic worldwide 
growing problem, characterization of HPV-associated molecular markers is key for 
determining new prognostic markers that would allow to develop new therapeutically 
approaches. Due to that the main objective of our study was to determine the association 
of cyclin D1 and HPV status in OPC patients and its relevance on their outcome. Our 
second objective was to find another clinical prognostic markers such as patients age, sex, 
alcohol and tobacco exposure, previous tumors, secondary tumors, tumor recurrence and 
type and treatment.  
 
     2. MATERIAL AND METHODS 
2.1. Patients and tumour tissue 
This is a retrospective case series. A total of 54 patients (n = 54) with primary OPC 
diagnosed at Hospital Universitario Marqués de Valdecilla between 2014-2018 were 
retrospectively selected. The years were chosen so that all patients have had at least 2 
years of follow-up after diagnosis. Patients information was collected through electronic 
medical records review from the hospital Database including age, gender, smoking status, 
alcohol intake, previous tumors, tumour location, treatment received, secondary tumours, 
tumor recurrence and type, follow-up time and survival status. Tumour staging using the 
TNM classification (41) was determined by review of clinical notes, radiology reports, 
surgical notes and pathology reports.  
2.2. P16 and Cyclin D1 immunohistochemistry 
Immunopathological study was carried out on formalin-fixed 4-µm-thick paraffin-
embedded tissue sections using the EnVision FLEX Visualization System (Dako, Agilent 
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Technologies, SL, Las Rozas, Madrid, Spain). Antibodies used in the immunohistochemical 
study are detailed in Table 2.1. The immunohistochemical reactions were performed using 
appropriate tissue controls. Automatic staining was accomplished on a Dako Omnis 
autostainer (Agilent Technologies, SL) Appropriate controls were used including normal 
tonsil (negative) and a known positive OPC case. P16 staining was considered positive only 
if there was strong nuclear and cytoplasmic staining that accounted more than 70% of 
tumor cells. Negative staining was considered when the staining was only nuclear, had a 
patch mosaic expression, had a marginal expression pattern or was absent (42). P16 
Immunohistochemistry was a used as a HPV subrogate marker and only implies positivity 
for HPV not for p16 subtype specifically. Cyclin D1 staining was considered positive when 
>50% of the specimen stained positive for it. 
ANTIBODY SOURCE CLONE DILUTION RETRIEVAL SOLUTION 
P16 DB Biotech R-19-D 1:100 High 
CYCLIN D1 Dako EP-12 FLEX-RTU High 
Table 2.1. Immunohistochemical antibodies used.  
2.3. HPV molecular study 
HPV molecular study was carried out on DNA extracted from 5 µm thick paraffin 
embedded sections. CLART HPV 4 kit (Genomica, Madrid) was used. This is based in viral 
DNA specific fragments amplification and hybridation with specific probes for each HPV 
type; it has 35 HPV subtypes (6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 
54, 56, 58, 59, 61, 62, 66, 68a y b, 70, 71, 72, 73, 81, 82, 83, 84, 85 y 89). Visualization was 
done with CLART- Strip. 
2.4. Statistical analysis 
Data was tabulated using Microsoft Excel (Microsoft Corporation, Redmond, WA, USA)  
and analyzed using SPSS/PASW Statistics (version 19, SPSS Inc., Chicago, IL). In order to 
compare dichotomous and categorical variables we used the Fisher´s exact test. 
Oropharyngeal cancer-specific survival was taken as time from cancer diagnosis until date 
of death or last medical consult. Kaplan-Meier method with log-rank test for determining 
statistical significance was used to estimate overall survival. Statistical significance was 
defined as p<0.05. 
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    3. RESULTS 
3.1 Clinicopathological data 
54 patients were identified to have primary oropharyngeal squamous cell carcinoma from 
the year 2014 to 2018 from the Hospital database of Hospital Universitario Marqués de 
Valdecilla. Several clinicopathological characteristics were analyzed and are summarized in 
table 3.1 and 3.2. Patients were categorized into two outcome groups based on disease 
status after treatment: Group 0 represented disease-free survival (54,5%) and deaths for 
other causes (10,9%); Group 1 represented disease-specific deaths (32,7%). Median age at 
onset was 64 years old (range 39 to 88 years). From all 54 patients 83,6% were males and 
21,8% had previous tumours. Most of the tumors were tumor stage T2 or T4, 17 cases 
(31%) and 16 cases (29%) respectively, followed closely by tumors larger than 4 cm or  
Table 3.1. Clinicopathological characteristics. Group 0: disease-free survival and patients who died for other 
causes; Group 1 represented disease-specific deaths.  
 
Clinical Characteristics Total (n=54) Group 0 (n=37) Group 1 (n=18) P value 
Sex 
Female  
Male 
       
 9 
 46 
 
 6 
31  
 
 3 
15 
 
1 
Smoking 
Yes  
no 
       
50 
 4 
 
34 
 2  
 
16 
 2 
 
0,594 
Alcohol intake 
Yes 
no 
       
46 
 8 
 
30 
 6  
 
16 
 2 
 
0,704 
Tumoral site 
Tongue base 
Palatine tonsil 
Lateral wall 
Posterior wall 
Palate  
Others 
       
21 
12  
 5 
 2 
 6 
 9 
 
14 
 8  
 3 
 2 
 2 
 8 
 
7 
4 
2 
0 
4 
1 
 
 
 
0,292 
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affecting the lingual surface of the epiglottis (T3) that were 14 (25%). Tumors of 2 cm or 
smaller (T1) were only 15% of the cases. Around one third of the patients did not present 
metastatic lymph nodes (36%), 15% had a metastatic ipsilateral lymph node 3 cm or 
smaller without extranodal extension (ENE) and most of patients were N2 (45%), which 
means that they have metastatic ipsilateral or bilateral positive lymph nodes between 3-6 
cm without ENE. Only 4% of the patients had N3  
Tumor Characteristics Total (n=54) Group 0 (n=37) Group 1 (n=18) P value 
T 
1 
2 
3 
4 
       
 1 
17 
14 
16 
 
 7 
11  
12 
 7 
 
1 
6 
2 
9 
 
 
0,04 
N 
0 
1 
2 
3 
       
20 
 8 
25 
 2 
 
13 
 6 
17 
 1   
 
 7 
 2 
 8 
 1 
 
 
0,882 
M 
0 
1 
       
53 
 2 
 
37 
 2  
 
16 
 0 
 
0,000 
Tumoral Stage 
1 
2 
3 
4 
       
 5 
 7 
 6 
 37 
 
 5 
 4 
 5 
 23   
 
 0 
 3 
 1 
14 
 
 
0,362 
Table 3.2. Tumoral characteristics. Group 0: disease-free survival and patients who died for other causes; 
Group 1 represented disease-specific deaths.  
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Clinical Characteristics Total (n=54) Group 0 (n=37) Group 1 (n=18) P value 
Treatment 
Surgery 
Surgery+CM 
Surgery+RT 
CM+RT 
Paliative CM 
RT 
Surgery+CM+RT 
       
10 
 1 
 1 
28 
 3 
 5 
 7 
 
 9 
 0  
 0 
20 
 0 
 2 
 5 
 
 1 
 1 
 1 
 8 
 3 
 3 
 2 
 
 
SG vs CM+RT 
p=0,268 
CM+RT vs  
SG+CM+RT 
p=0,526 
 
Relapse 
yes 
no 
       
40 
15 
 
32 
 5  
 
 8 
10 
 
0,003 
Type of relapse 
Locoregional  
Metastasis 
LR+MT 
Local 
Regional 
 
3 
3 
2 
1 
2 
 
 0 
 2  
 0 
 1 
 2 
 
3 
1 
2 
2 
4 
 
 
0,17 
Table 3.3. Patients treatment and relapse. Group 0: disease-free survival and patients who died for other 
causes; Group 1 represented disease-specific deaths. CM: chemotherapy, RT: radiotherapy, LR: locoregional. 
stage disease. Only 4% presented metastasis at diagnosis. When looking at patients overall 
survival (OS) it was, surprisingly, only related to its T stage (Fig. 3.1) but not its N stage (Fig. 
3.2). Indeed, when we compared N1 (75% OS), N2 (56,7 OS) and N3 (50% OS) patients to 
N0 (65% OS) ones we did not find a significant decrease in survival (p=0,856), (p=0,585) 
and (p=0,505) respectively. Moreover, T1 and T3 stage tumors exhibited the same survival 
(87,5% and 85.6% respectively) whereas T2 tumors showed a poorer survival 64,7% after 
at least two years follow-up although not statistically significant. T4 tumors survival was 
43,8%. The vast majority of patients were classified as stage IV disease at diagnosis 
(67,3%), while only 9,1%, 12,7% and 10,9% were stage I, II and III respectively. In regards to 
survival, all patients diagnosed with stage I disease survived whilst stage II patients had the 
worse survival rate (57,1%) even in comparation with stage IV patients (62,2%) although 
not significant. Stage III patients survival was (83,3%). 
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Fig. 3.1. Kaplan-Meier log-rank test survival analysis for comparison between T stage groups. 1 (Blue): T1, 2 
(Red): T2, 3 (Green) T3, 4 (Orange): T4 (p=0,04).  
 
Fig. 3.2. Kaplan-Meier log-rank test survival analysis for comparison between N stage groups. 0 (Blue): N0, 
1 (Red): N1, 2 (Green) N2, 3 (Orange) N3. When comparing N1, N2 and N3 to N0 we did not find a significant 
decrease when looking at survival (p=0,856), (p=0,585) and (p=0,505) respectively.  
Patient treatment and relapse data is summarized in table 3.3. Most patients (50%) were 
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A. 
treated with chemotherapy and radiotherapy and exhibited a survival rate of 71.4% that 
was even slightly higher although not significant when surgery was added to the regime. 
18% of patients were treated solely with surgery with a 90.1% survival rate but it was not 
significantly higher than when treated with chemotherapy and radiotherapy alone 
(p=0,268). During the follow-up recurrence was observed in 15 cases, while 10 patients 
died of the disease (p=0,003). Survival did not differ among different types of relapse 
mostly due to a small sample so further patients should be studied to confirm this. No 
statistical significance was found among patients including alcohol intake, smoking, age, 
sex, tumor location and tumoral stage between the two groups.  
Histopathological characteristic are summarized in table 3.4. Only 20% of tumors were 
keratinizing tumors (Fig 3.3 A) and there were not significantly differences in overall 
survival compared with nonkeratinizing tumors (Figure 3.3 B) (p=1). 
Histological 
Characteristics 
Total (n=54) Group 0 (n=37) Group 1 (n=18) P value 
Keratinizing 
yes 
no 
       
11 
44 
 
 8 
29  
 
3 
15 
 
1 
HPV 
Positive 
negative 
       
18 
36 
 
15 
16 
 
3 
20 
 
0,035 
 
Cyclin D1 
Positive 
negative 
 
18                                       
36 
 
10 
26 
 
8 
10 
 
0,422 
Table 3.4. Histological characteristics. Group 0: disease-free survival and patients who died for other causes; 
Group 1 represented disease-specific deaths. HPV: human papillomavirus. 
                     
Figure 3.3. Tumor keratinizing state. A) Keratinizing tumor with tumor cells nets presenting round to oval 
nuclei, inconspicuous nucleoli, and high mitotic activity (Hematoxylin and eosin, magnification 10X) B) 
Nonkeratinizing tumor with well circumscribed tumor cells nets that have round to oval 
nuclei, inconspicuous nucleoli, and high mitotic activity (Hematoxylin and eosin, magnification 20x). 
B. 
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3.2 HPV status and p16 expression 
HPV status was analyzed by both immunohistochemistry (Fig. 3.4) and by molecular study 
allowing HPV subtypes determination.  P16 analysis is summarized in table 3.2. 
 
Figure 3.4. p16 expression. p16 positive specimen showing strong 
and diffuse expression in cytoplasm and nucleus in > 70% of tumor cells 
(x20). 
 
 
 
                IHC HPV 
POSITIVE NEGATIVE 
14 40 
DNA 
YES 
 
 
NO 
 
11   
 
 
3  
  PCR  
Positive    11 
Negative    0 
 
14         
 
 
26 
PCR  
Positive     7 
Inhibited    7 
Table 3.2. HPV status and P16 analysis resume. DNA: yes: there was sufficient sample to perform PCR based 
in situ hybridization. No: there was no DNA in the sample. PCR: positive: DNA sample amplified and 
hybridized with any of the HPV probes. PCR: inhibited: It was not possible to obtained a PCR product to 
hybridized. IHC: immunohistochemistry. 
We were not able to isolate DNA from 50% of samples most of them collected from older 
periods. Seven patients that were negative in the immunohistochemistry were positive for 
p16 when analyzed by molecular study so they were considered false negatives. A 33,3% 
of patients (n=18) tested positive for HPV with a survival rate of 85,7% compared to the 
58,3% that exhibited HPV negative patients (p=0,035) (Figure 3.5). Moreover, when we 
look for high risk HPV subtypes we found that 50% of the patients did not tested positive 
for p16 but for other HR-HPV subtypes. 22,2% patients were also positive for 58 and 53, 
16,6% 59 and 11%  84, 66, 60, 31 and 18. In addition 38,8% of patients were coinfected by 
2 or more HR-HPV subtypes and 2 patients were coinfected by 6 different HPV subtypes.   
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Figure 3.5. Kaplan-Meier log-rank test survival analysis for comparison between HPV positive and negative 
subgrups. 0 (Blue): HPV negative, 1 (Red): HPV positive (p=0,035). 
Absence of alcohol intake or smoking was not significantly related to HPV positive tumors 
(p=0,24) and (p=0,28) respectively. 50% of patients that have a significant alcohol intake 
and 56% of smokers were also positive for HPV. In addition, HPV expression was not seen 
to have tropism to any anatomical site.  
3.3 Cyclin D1 expression 
Cyclin D1 expression was analyzed by immunohistochemistry. Positivity was considered 
when more than 50% of tumoral cells were positive for this protein (Fig. 3.6). 33,3% of the 
patients samples stained positive for cyclin D1. Media was 38,18 ± 26,46 ED. Cyclin D1 
positive patients overall survival was 55,6% compare to 72,2% for Cyclin D1 negative 
patients although not significant (p=0,422) (Fig. 3.7). 
  
Figure 3.6. Cyclin D1 immunohistochemistry. Positive cyclin D1 
immunohistochemistry showing an intense nuclear brown staining in tumor 
cells (> 90%) (40x).  
 
 
From 21 patients that were high risk HPV positive only 4 were cyclin D1 positive too. 
Overall survival for HPV+/cyclin D1 positive patients was 75% in contrast to 88,2%  for 
HPV+/cyclin D1 negative patients (p=0,933).  
17 
 
 
 
Figure 3.7. Kaplan-Meier log-rank test survival analysis for comparison between A) HPV+ patients cyclin D1 
positive or negative B) HPV- cyclin D1 positive or negative C) Cyclin D1 positive and negative subgrups. 0 
(Blue): Cyclin D1 negative, 1 (Red): Cyclin D1 positive (p=0,933). 
42,4% of HPV negative patients were cyclin D1 positive and its overall survival was 50% 
compare to 57,1% for cyclin D1 negative patients (p=0,896). Cyclin D1 expression was not 
related with either T or N status or to any anatomical site location.  
5. Discussion 
In the last decades considerable effort has been made in order to determine new 
oropharynx cancer prognostic markers. Thanks to it, HPV infection has been associated in a 
not negligible group of patients with OPC carcinogenesis and has been widely related to 
better survival rates. Indeed, that has led to a TNM understratification for HPV positive 
patients as embodied in the last TNM guidelines (8º edition).  However, differences in the 
techniques used, IHC or PCR based in situ hybridization arrays suggest variability among 
groups. Our results support the impact of HPV in OPC patients overall survival. 38,8% of 
our cohort was positive for HPV and their OS was greater than patients without HPV 
infection although they share other main risk factors as tobacco smoking and alcohol 
which weren´t different among groups. Strikingly, our cohort had a higher number or HPV 
patients (38,8%) compared to others studies contradicting previous findings that indicated 
B. 
C. 
A. B. 
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Southern Europe to have the lower rates of OPC HPV positive tumors. One of them 
prevalence was 7.6%-9.4% and globally around 20% (12) and another metanalysis found a 
24.2% in Southern Europe, around 18% in Spain and globally 45.8% (43). This suggest that 
HPV OPC infection is rising rapidly in the last years even passing Western Europe countries 
prevalence that is around 32-38% (12, 43). It is necessary to point out that we were not 
able to obtained DNA for analysis in 50% of our samples suggesting that our HPV positive 
percentage might be underestimated and therefore further analysis should be done in 
order to obtain a reliable data. The discrepancies may be explained by differences in the 
geographic origin of the samples, as well as the techniques used among studies to obtain 
HPV data. For instance, some studies only assess as said in the guidelines p16ink4a by 
immunohistochemistry as a read out for HPV positivity. However, several studies have 
determined the necessity to another marker in order to determine an active HPV infection 
changing the paradigm of HPV positive to HPV-driven OPC. p16ink4a determination together 
with E6-E7 RNA (43) or HPV PCR based molecular analysis (44) are currently the gold 
standard as done in our study. Furthermore when using PCR based molecular analysis with 
different HR-HPV probes we were able to determine that 50% of HPV-driven OPC are not 
only due to 16 subtype but due to other subtypes. This might explain the low prevalence 
of HPV in some studies as some of them only determine HPV-16 subtype. In addition 
several cohorts have pointed HPV-16 as the main subtype accounting for more than 95% 
(11, 17) or 85% (45) followed by 33 and 35 or 60% of cases (46) followed by HPV 33, HPV 
26, HPV 35, and HPV 18 (12) which contrast with our results that found 59, 58 and 53 as 
the most prevalent ones after p16 (50%). Moreover, other studies have seen that multiple 
HPV infections in OPC patients are rare 5% that is in high contrast with our results that 
found 38% of tumors co-infected with 2 or more subtypes. This might be explained as HPV 
subtypes different distribution among populations, sexual behaviors among them (47), and 
the rising epidemic of HPV.  
In this study, we observed that OPC patients disease specific survival rate was 67.3 % 
which was significantly associated besides to HR-HPV presence with T status. However we 
have not found a significant correlation between N status and survival which can be 
explained as we took patients initial TNM for the study that was obtained using the 7º 
edition TNM guidelines. This might be explained considering that the T classification 
remains the same, except for carcinoma in situ (Tis) and T4b category that have been 
removed from HPV-positive disease whereas in HPV-related carcinoma a downstaging in N 
criteria, as explained in the introduction, has been done (25). Indeed, only 30% of N0 
patients were HPV-positive whereas 62% were N1, 41% were N2 and 0% were N3 
indicating overstaging as a possibility to explain the lack of differences in OS among 
groups. 
Even though HPV status has improve prognostic stratification there are still some patients 
that have a more aggressive and lethal disease within this group suggesting the need for 
new biomarkers to better predict HPV positive patients outcome. Cyclin D1, as a cell cycle 
regulator, is striking marker to consider since its overexpression has been related to worse 
prognosis in several cancers including some types of breast cancer (48, 49), esophageal 
19 
 
(50), gastric (51) and most importantly HPV positive cervix cancer (52-54). Indeed several 
authors have consistently related cyclin D1 overexpression or amplification with poor 
prognosis of different head and neck tumors (55) (56) including oropharyngeal ones (57, 
58). Authors strongly converge in that cyclin D1 expression is downregulated in most HPV 
positive tumors (28, 50, 59, 60). Indeed, when we look at Cyclin D1 expression in HPV 
positive patients only 19% of them stained positive for cyclin D1 in more than 50% of 
tumoral cells, which matches other cohorts percentages (28, 57, 61). However, few 
studies have evaluated HPV and cyclin D1 relationship, and findings are not consistent and 
diverge, although several authors have pointed Cyclin D1 overexpression as a poor 
outcome predictor in 16 positive OCP patients (28, 59, 60, 62). When we looked at Cyclin 
D1 implication in HPV positive patients prognosis in our cohort we did not find any 
significant association. This can be mostly explained due to our limited patient number so 
further patients should be checked in order to affirm this firmly. However, there is 
another important factor to take into consideration since there is not a consensus about 
cyclin D1 cutoff for positivity since it ranges between 5-50% depending on the cohorts. 
Differences in immunohistochemistry protocols as well as in cyclin D1 antibodies can also 
influence. Moreover, cyclin D1 overexpression has been related with radioresistance (63) 
and patients treatment regimes varies among them. In addition patients economic status 
might influence affecting OS, whereas in Spain this last variable is not present. Lastly 
differences in HPV status evaluation, as explained before, might also influence in these 
results.  
To sum up, HR-HPV infection is present in 38% of patients, which correlates with better 
outcome, being 16 the most prevalent subtype (50%) and multiple HPV infections are seen 
in 38% of patients. In addition low cyclin D1 expression is related to HPV positive patients 
but its overexpression is not related with an increased risk of death in HPV positive 
patients although further patients should be analyzed in order to corroborate it.  
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